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Impact of Aging on Liver Cells and Liver 
Disease: Focus on the Biliary and Vascular 
Compartments
Leonardo Baiocchi,1 Shannon Glaser,2 Heather Francis,3,4 Lindsey Kennedy,3,4 Eric Felli,6 Gianfranco Alpini ,3,4* and 
Jordi Gracia- Sancho 5,6*
The aging process is represented by the time- dependent decay in physiologic functions of living beings. Major interest 
has been focused in recent years on the determinants of this progressive condition due to its correlative relationship 
with the onset of diseases. Several hallmark features have been observed in aging, such as genetic alterations, mito-
chondrial impairment, and telomere shortening. At the cellular level, a senescent phenotype has been identified in re-
sponse to aging that is characterized by a flat appearance, proliferative arrest, and production of specific molecules. The 
net effect of these cells in the course of diseases is an argument of debate. In fact, while the onset of a senescent phe-
notype may prevent tumor spreading, these cells appear to support pathological processes in some conditions. Several 
studies are now focused on clarifying the specific molecular pathways of aging/senescence in different cells, tissues, or 
organs. Biliary and vascular components, within the liver, have emerged as important determinants of some form of 
liver disease. In this review we summarize the most recent achievements on aging/senescence, focusing on the biliary 
and vascular liver system. Conclusion: Several findings, in both preclinical animal models and on human liver specimens, 
converge in supporting the presence of specific aging hallmarks in the diseases involving these hepatic compartments. 
(Hepatology Communications 2021;5:1125-1137).
Aging recapitulates the several processes impairing pathophysiological functions and homeostasis of a living organism over time. 
In aged organisms, including humans, several bio-
chemical and cellular systems undergo a progressive 
time- dependent impairment such as mitochondrial 
respiration, stem cell reserves, and genome repair 
function.(1) The possibility to counteract the delete-
rious effects of aging requires an in- depth knowledge 
of different intracellular mechanisms involved in this 
process. In fact, several studies have focused on this 
target during the past few decades.(2) In 1939, the 
first observations of a prolonged life span in rodents 
maintained at a low caloric intake(3) were made; and 
we are now using senolytic treatment in clinical tri-
als.(4) Moreover, possible individual aging patterns 
have been recently suggested in humans by multi- 
omic analysis.(5) Aging effects on the liver appear to 
be less relevant than those on heart, kidney or brain, 
possibly due to the specific enhanced regenerative 
properties of the liver.(6,7) However, important hepatic 
deleterious changes occur with time, also demon-
strated in the clinical setting observed by suboptimal 
outcomes of liver- transplanted patients with hepatitis 
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C virus (HCV), when older donors were used.(8) In 
this review, we discuss the specific aging- related bil-
iary and vascular liver phenotypes, including those 
observed at the cellular/molecular level and with 
regard to liver diseases.
Liver Aging and Cellular 
Senescence
Liver aging is associated with impaired prolifera-
tive and metabolic functions. With regard to this lat-
ter point, evidence suggests that changes occurring in 
the liver over time may have a role in susceptibility to 
nonalcoholic fatty liver disease (NAFLD).(9) Linked 
to the concept of tissue aging, cellular senescence has 
been recognized as the most important age- associated 
phenotypic change.(10) Cellular senescence is an irre-
versible halt of cell cycle progression; thus, the cell 
is no longer able to proliferate but can remain met-
abolically active.(11) This process was first described 
in the early 1960s in diploid cell cultures, in which 
the exhaustion of replicative cell capacity over time 
led to a senescent phenotype characterized by growth 
arrest.(12) Cellular senescence, together with auto-
phagy and apoptosis, participates in the network of 
the possible cellular response to stress; in contrast, 
autophagy (a process removing damaged intracel-
lular organelles or molecules) has been suggested to 
promote senescent transformation in some cases.(13) 
Although the onset of senescence is postulated to be a 
protective mechanism against malignant transforma-
tion during aging, the secretion of several molecular 
factors, termed senescence- associated secretory phe-
notype (SASP), is triggered by these cells.(14) SASP 
contribute to several biological processes such as 
angiogenesis, tissue inflammation, and repair. At the 
same time, SASPs are able to maintain and to diffuse 
(in the neighboring cells) the senescence phenotype 
through autocrine and paracrine mechanisms.(14,15) 
Although the correlation between tissue aging and 
cellular senescence may be, in part, supported by 
the possible accumulation of genomic injuries and/
or mutational signals during time, the major role in 
this process appears to be played by telomere short-
ening.(16) This time- dependent reduction of telomeres, 
which is a loss of a maximum of 200 kD at the end 
of any replicative cycle, in the end determines apop-
tosis or the onset of the senescence phenotype.(17) 
This process is generally regarded as the form of rep-
licative senescence; however, a premature senescence 
may also arise in particular conditions of cellular stress 
and damage.(14) Finally, telomere shortening and/or 
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cellular senescence has been consistently reported in 
human liver diseases,(18,19) suggesting their possible 
role in these maladies that present a worst outcome 
in aged livers.
Biliary and Vascular 
Compartment Interplay
The anatomical relationship between the bili-
ary and the vascular component within the liver was 
already described by the identification, by means of 
scanning electron microscopy coupled with liver cast-
ing, of the peribiliary- vascular- plexus (PBP).(10,20) A 
graphical representation of the relationship between 
PBP and biliary tract is depicted in Fig. 1. Originating 
from lateral branches of the hepatic artery, the PBP 
reaches the sinusoids with small direct anastomotic 
vessels or interconnecting with vessels of the portal 
vein, and becoming narrow when surrounding smaller 
ducts. A physiological cooperation occurs between the 
biliary tract and PBP, as the latter supports cholan-
giocyte nutrition and recirculation of biliary compo-
nents back again to the liver.(21) The strict relationship 
between the biliary compartment and PBP is further 
confirmed by the parallel proliferation of these two 
different systems during injury, as observed in bile 
duct ligated (BDL) rats.(21) Moreover, cross- talk 
occurs between the biliary and vascular compartment 
during normal, developmental, or pathological con-
dition, primarily through vascular endothelial growth 
factor (VEGF) and angiopoietin 1 and 2.(21- 24) With 
regard to VEGF, this is produced by cholangiocytes 
and supports their growth with an autocrine mech-
anism. Moreover, in a rodent model, this mediator is 
capable of counteracting PBP vanishing induced by 
hepatic artery ligation.(21) Taken together these data 
support the idea of a unique physiologic system in 
which biliary and vascular functions are integrated.
Biliary Epithelium
The biliary epithelium is lined by cholangio-
cytes, which contribute to qualitative and quantita-
tive changes in bile secretion/composition, before its 
release in the duodenum.(25) Bile acid– independent 
ductal bile secretion is sustained primarily by the activ-
ity of secretin (Sec)/secretin receptor (SR) pathway 
Fig. 1. Schematic representation of biliary tract and peribiliary vascular plexus assembly. The main functions of peribiliary vascular plexus, 
in supporting biliary tract activities, are reported in the gray box on the right side. (This figure was made with BioRender.com under a 
purchased license agreement.)
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within these cells.(25,26) Following stimulation with its 
ligand, SR activates cyclic adenosine monophosphate/
protein kinase A/cystic fibrosis transmembrane con-
ductance regulator/Cl- /HCO3
-  exchanger signaling, 
thus simulating a bicarbonate- enriched choleresis.(27) 
However, different from other liver cells, numerous 
hormones and hormone receptors are expressed by 
cholangiocytes, which regulate not only the secretive, 
but also the proliferative, response in normal as well 
as in pathological conditions. Moreover, several other 
organic molecules, such as bile acids, angiogenic fac-
tors or neuropeptides, modulate the activities of the 
biliary epithelium, suggesting cholangiocytes to be the 
main liver collectors of signals coming from circulat-
ing molecules.(28) Finally, bile duct cells are composed 
of two different cellular types: small cholangiocytes 
and large cholangiocytes, lining small and large ducts, 
respectively.(29) Large cholangiocytes are those pro-
moting the main physiologic activities of biliary tract 
such as secretion, response to hormones, and media-
tors.(29) In contrast, small cholangiocytes are consid-
ered a quiescent population that is able to proliferate 
and acquire the large cholangiocytes phenotype when 
these are damaged.(29)
Aging of the Biliary 
Epithelium
Age- related impairment of cholangiocytes has 
emerged as an important field of research in the last 
decade. The evaluation of the aging processes may, in 
fact, shed light on the mechanisms of adult chronic 
cholestatic liver diseases. Among the latter, primary 
biliary cholangitis (PBC) and primary sclerosing chol-
angitis (PSC) are the most represented in humans.(30) 
PBC, the most frequent autoimmune liver disease 
with a prevalence of approximately 30/100,000, gen-
erally affects middle age women and is characterized 
by the presence of circulating anti- mitochondrial anti-
bodies.(31) From a pathological point of view, the dis-
ease presents as a lymphocytic cholangitis that may 
evolve in ductopenia and fibrosis. PSC is less fre-
quent, with a male- to- female ratio of 2:1. Abundant 
deposition of scar tissue, determining strictures of the 
biliary tract, is the main hallmark of the disease.(32) 
Both PBC and PSC are conditions affected by a sig-
nificant morbidity and mortality, whereas a definitive 
pharmacological treatment for severe cases has not 
been identified so far. This perspective, among the 
other molecular aspects also related to the aging pro-
cess, deserves interest.
In the context of biliary damage, modulation of bil-
iary senescence during cholestatic damage has become 
of increasing interest. Indeed, enhanced biliary senes-
cence, specifically in ductular reactive cells, has been 
found in chronic liver diseases, particularly in PBC.(11) 
Additionally, enhanced biliary senescence correlates 
with fibrosis progression in chronic liver diseases.(11) 
Telomere shortening, which was stated previously as 
a key aspect of senescence, has been found in human 
PBC samples,(33) and the effect of biliary senescence 
on PBC outcomes has been largely studied.(34- 36) 
Cholangiocytes isolated from patients with PSC show 
exacerbated senescence and SASP marker expression 
compared with other cholestatic diseases.(19) Similarly, 
in a 3D organoid model using PSC cholangiocytes, 
these “cholangioids” displayed senescent and SASP 
features, which promoted macrophage recruitment 
and number.(37) The role of senescence/SASP in bil-
iary injury has been demonstrated; thus, evaluation 
of targeting this axis for therapeutic use is of great 
interest.
Data FRom eXpeRimental 
moDels
As previously discussed, the main cellular response 
to the aging process is represented by the onset of 
a senescent phenotype. Morphologically these cells 
are larger, with increased cytoplasm/nuclear ratio, 
and present an increased number of vacuoles(14) The 
tumor suppressor retinoblastoma protein and p- 53 are 
considered the main molecular routes for the induc-
tion of senescent phenotypes.(38) A cellular increase of 
cyclin- dependent kinase inhibitors is found in senes-
cent phenotype. Among these, p21 and p16 are usually 
considered as appropriate markers to establish the rate 
of senescence of a specific tissue in normal and patho-
logical conditions. In addition, levels of senescence- 
associated- β- galactosidase (SA- β- gal), an enzyme 
present in lysosomes, has been generally regarded as 
an important biochemical indicator of senescence and 
has been used widely in research.(39) Senescent hall-
marks have been studied in preclinical models of both 
PBC and PSC. One study focused on Forkhead box 
A2 (FoxA2) activity during experimental cholestasis 
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in BDL and multidrug- resistant knock- out (Mdr2−/−) 
mice.(40) FoxA2 is regarded as an important regula-
tor of cell differentiation, and the model of cholesta-
sis is characterized by the decrease of this molecular 
mediator.(41) In this study, an inverse relationship was 
observed between FoxA2 expression and hallmarks 
of senescence such as p16 expression or SA- β- gal 
staining in liver section. Interestingly, FoxA2 res-
toration obtained by small cholangiocyte cell ther-
apy determined an important reduction of senescent 
phenotype.(40) These data were extended by a study 
examining the role of substance P (SP), a tachykinin 
family neuropeptide, in the same preclinical models 
of murine cholestasis (BDL and Mdr2−/−).(42) The 
interest regarding SP and biliary tract came by obser-
vations demonstrating (1) decreased cholangiocar-
cinoma (CCA) cells growth and (2) BDL- induced 
biliary proliferation, after inhibition or genetic sup-
pression of the specific SP receptor neurokinin- 1 
(NK- 1R).(43,44) When senescent features were exam-
ined in both cholangiocytes and hepatic stellate cells 
(HSCs) coming from cholestatic rodent, these were 
increased in bile duct cells, while the opposite behavior 
(less senescence, more cellular activity) was observed 
in HSCs, thus resulting in increased collagen depo-
sition and fibrosis. Moreover, in this study, the SP/
NK- 1R pathway played a major role in differential 
modulation of cholangiocyte– HSC senescence bal-
ancing, as inhibition of NK- 1R increased biliary tract 
viability and reduced profibrotic processes. Although 
the specific mechanism linking SP/NK- 1R to differ-
ential cellular senescence remains undetermined, this 
research showed that possible regulation of senescent 
phenotype in different cells might be a possible target 
for therapy.(45) The relationship of the main secretory 
and proliferative cholangiocyte pathway, the Sec/SR 
axis was also examined with regard to cellular senes-
cence in preclinical models of cholestasis. In BDL 
mice, knockout of the SR gene reduces hyperplasia(46) 
and inhibition of Sec/SR axis; in Mdr2−/− mice, it 
ablates the transforming growth factor beta 1 (TGF- 
β1)– mediated enhanced liver fibrosis.(47) Changes 
in cellular senescence processes were evaluated in a 
study examining the double SR−/−/Mdr2−/− knockout 
mice.(48) The Sec/SR system exhibited effects similar 
to those observed with regard to SP. In fact, genetic 
ablation of SR greatly reduced fibrosis and prolifer-
ation, down- regulating cholangiocyte senescence and 
up- regulating the senescent phenotype of HSCs. This 
view was corroborated by data from the BDL model 
of Sec−/−/SR−/− mice.(47) Again, the differential effect 
of Sec/SR on cholangiocytes– HSC senescence was 
confirmed; moreover, these findings were extended, 
suggesting that Sec- related effects were achieved by 
TGF- β1/TGF- β1R stimulation.(47) In the last few 
years, other biomolecules such as α- Calcitonin gene- 
related peptide (α- CGRP), stem cell factor (SCF), 
or vimentin have been demonstrated to participate 
in experimental cholestatic injury, differentially reg-
ulating cholangiocyte and HSC senescence. In the 
α- CGRP−/− mouse model, the typical senescence 
phenotypic distribution (cholangiocytes+; HSCs−) 
observed with BDL and in parallel with cholestatic 
damage was reverted.(49) Accordingly, several senes-
cence markers were decreases in cholangiocytes, 
such as p16, p21, chemokine (C- C motif ) ligand 2 
(CCL2), and plasminogen activator inhibitor 1 (PAI- 
1). SCF signaling also modulates experimental choles-
tatic biliary damage, as demonstrated by reduction 
of cholangiocytes injury/senescence when its axis is 
ablated.(50) Similar results are also obtained by target-
ing vimentin. Its inhibition improves biliary damage 
and cellular senescence, possibly interfering with the 
epithelial to mesenchymal transition (EMT) process 
of bile duct cells, a mechanism linked to the onset of 
fibrosis.(51) Finally, the direct targeting of senescent 
cellular machinery has been attempted, in experi-
mental systems, to improve pathological features. 
Inhibition of the cyclin- dependent kinase inhibitor 
p16 has been obtained in a model of cholestasis by 
the administration of p16 morpholino. This strategy 
decreased senescence, secretion of SASP, and ductular 
reaction in Mdr2−/− mice.(52) In another experimen-
tal approach, B- cell lymphoma, extra- large (Bcl- xL) 
inhibition determined apoptosis of both senescent 
cholangiocytes and activated fibroblast, thus reduc-
ing liver damage in a Mdr2−/− rodent model.(53)  In 
contrast, Bcl- xL overexpression, in the course of 
cholestatic injury, was related to ETS proto- oncogene 
factor 1 and p300 cooperation.(54) In conclusion, the 
data coming from experimental studies support the 
hypothesis of a unifying model linking ductular reac-
tion, EMT, fibrosis, and the differential cholangiocyte/
HSC cellular senescence in an integrated machinery 
that determines chronic cholestatic liver diseases. This 
picture may be implemented in the future including 
also the role of mast cells. During liver injury, mast 
cells surround the biliary tract and play a critical role 
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in the contribution by driving a senescent phenotype, 
thus promoting damage.(55) The main molecular fac-
tors, supporting cholangiocyte senescence in experi-
mental models of cholestasis, are summarized in Fig. 
2. Correlative findings in human are reported in the 
following section.
Human stuDies
Several aspects observed in animal models related to 
aging, such as telomere shortening, cellular senescence, 
DNA alteration, mitochondrial impairment and oth-
ers, have been also observed in human liver.(56) These 
changes may impair the physiologic defense against liver 
injury or they could enhance pathological pathways with 
lipids accumulation, as observed in NAFLD.(57) With 
regard to cholestatic diseases, for instance, more severe 
evolution of PBC are usually observed in middle- aged 
women, with the postmenopausal drop of protective 
estrogens.(58) However, in addition to unrelated liver 
aging factors that may worsen cholestatic injury, as in 
the previous case, specific aging hallmarks have been 
identified in human liver affected by disease of the bil-
iary tract. Cholangiocytes freshly isolated from patients 
with PSC are enlarged, with tight junction defects, 
and stain positive for SA- β- gal (marker of senescence) 
in nearly 50% of cases.(59) These cells also exhibit an 
increase production of SASP, such as interleukin (IL) 
6 and IL- 8. In another study, comparison of liver tissue 
coming from healthy subjects and patients with PSC, 
PBC, and HCV demonstrated a maximum increase of 
markers of cellular senescence (p16) and SASP secre-
tion (IL- 6, IL- 8, CCL- 2, and PAI- 1) in patients with 
PSC, followed by those with PBC.(19) Patients with 
HCV exhibited cellular senescence features similar to 
the healthy control. Finally, in the same research, nor-
mal human cholangiocytes exposed to different dam-
aging agents within 10 days evolved toward a senescent 
phenotype with production of SASP. Another study 
examined the hallmarks of senescence in human 
PBC liver tissue as a function of clinical outcome and 
response to therapy.(60) This study demonstrated that 
(1) the number of senescent cells was proportional to 
the severity of the disease, and (2) increased expression 
of p16 was related to an inadequate response to ursode-
oxycholic acid standard therapy.
Taken together, these findings suggest that cholan-
giocyte senescence might be a characteristic feature of 
Fig. 2. The molecular determinants of cholangiocyte senescence, identified in experimental models of cholestasis. (This figure was made 
with BioRender.com under a purchased license agreement.)
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biliary tract diseases, and that senescent phenotypes 
would rise as a standard response of these cells to dam-
age. Other correlative studies matching rodent and 
human samples supported this view. In a previously 
mentioned study, FoxA2 activity was nearly undetect-
able in human PSC or PBC liver specimens, whereas 
SASP levels (TGF- β1) were increased.(41) The possi-
ble link between SP and cellular senescence in PSC 
was suggested by the finding of increased blood levels 
of this neuropeptide and its messenger RNA in liver 
of subjects affected by an advanced stage of this dis-
ease.(42) Other correlative assessments regarding α- C-
GRP, SCF, or vimentin levels were carried out in PSC 
human tissue to confirm the preclinical data obtained 
in rodents, as previously described.(49- 51) Finally, 
increased levels of twinfilin- 1 were detected in chol-
angiocytes of patients with PBC or PSC. This pro-
tein, in experimental cholestasis, appeared to respond 
to several microRNA signals and to play a major role 
in supporting the proliferative/senescent evolution of 
bile duct cells in this setting.(61)
With regard to other biliary diseases, cellular 
senesce was also examined in biliary atresia, which is a 
pediatric progressive cholestatic disease characterized 
by the preferential obliteration of the extrahepatic bil-
iary duct.(62) In a study, liver evaluation of cell cycle 
regulators p16 and p21 was carried out in 80 patients 
with biliary atresia. The results evidenced a constant 
occurrence of cellular senescence in this disease, 
similar to other forms of injury of the biliary tract. 
Moreover, a possible relationship with the progression 
of injury was suggested.(63) In conclusion, preclinical 
animal and human data strongly support the role of 
aging, and in particular of cellular senescence, in the 
molecular machinery at the base of chronic cholestatic 
human diseases. Two aspects are particular intriguing 
at present: (1) how cellular senescence contributes 
in an integrated process with inflammation, ductular 
reaction, EMT, and fibrosis in the maintenance of 
the disease; and (2) how to attain a different regula-
tion of cholangiocyte and HSC senescence, to reduce 
injury in the course of the diseases of the biliary tract. 
Further studies will hopefully answer these questions.
Liver Sinusoid
The hepatic vascular compartment has a unique 
structure that allows maintenance of liver homeostasis. 
Liver blood flow enters into the liver through two ves-
sels, the portal vein and the hepatic artery, altogether 
supplying the hepatic tissue with oxygen, nutrients, 
hormones, and other substances including inflamma-
tory factors and toxins. The segment of the hepatic 
microcirculation where the exchange of substances 
occurs is the hepatic sinusoid, a unique vascular bed 
consisting of a layer of liver sinusoidal endothelial cells 
(LSECs) surrounded by vascular perisinusoidal cells 
(HSCs), and flanked by plates of nonparenchymal 
cells or hepatocytes. The thin area where HSCs reside 
is called the space of Disse. In addition, the hepatic 
sinusoid houses an important part of the phagocytic 
system, Kupffer cells (KCs), the resident macrophages, 
and other immune cells like T lymphocytes and pit 
cells (also known as hepatic natural killer cells), alto-
gether making the liver a key organ for innate immune 
system.(64) Immune cells are anchored to the luminal 
side of the sinusoidal endothelium, and therefore 
are exposed to the bloodstream. The complex func-
tions of the liver in molecule biosynthesis, metabo-
lism, inflammation, and clearance of bloodstream are 
tightly dependent on an adequate microcirculation, 
guaranteed by a healthy phenotype and proper para-
crine signaling within the liver sinusoid.(65)




LSECs are specialized endothelial cells that form 
the vascular wall in the liver sinusoids. In normal 
conditions, LSECs form a permeable barrier due to 
fenestrae presence in their membrane and due to 
absence of basal membrane. These properties make 
the liver endothelium discontinuous, increasing 
crosstalk between hepatocytes and liver sinusoidal 
cells. LSECs also play a role in regulating hepatic 
vascular tone through the production of vasoactive 
molecules.(66)
Data from experimental models demonstrated 
that LSECs de- differentiate during healthy aging, a 
process initially defined by partial loss in the num-
ber and diameter of fenestrae, also termed as pseudo- 
capillarization.(67) Subsequent studies improved the 
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description of LSEC de- differentiation in aging, 
clearly defining that such distinctiveness was not lim-
ited to morphologic changes but accompanied by sig-
nificant deregulations in the LSEC phenotype.(68,69) It 
has been described that alterations in key vasodilatory 
pathways, including the nitric oxide one, may contrib-
ute to increment the hepatic vascular resistance. The 
reduction in vasodilators is of relevance considering 
the roles of nitric oxide regulating the hepatic vascu-
lar tone,(70,71) exerting anti- inflammatory effects and 
maintaining other nonparenchymal cell phenotypes 
through paracrine interactions.(72,73) Aged LSECs 
exhibit decreased expression of diverse angiocrine 
receptors (e.g., SE- 1, stabilin- 2 [Stab2], kdr) and 
angiocrine factors (including wingless- type [wnt2] 
and hepatocyte growth factor [hgf ]), which may affect 
hepatocyte regeneration.(69,74) LSECs are in a mod-
erate pro- inflammatory state, which, together with 
down- regulation of sirtuin 1 and up- regulation of p16, 
suggest senescence of this cell type in aging.(75) Finally, 
LSEC scavenger functions are also compromised in 
aging, as demonstrated by the reduction in endocytic 
capacity.(76) Interestingly, a recent study suggested that 
scavenger capacity dynamics during a lifespan would 
be a key mechanism to promote LSEC senescence.(75) 
Middle- aged mice exhibit a significant increase in 
scavenger receptors expression, which may fuel the 
intake of toxic substances, ultimately leading to mito-
chondrial oxidative stress and senescence. Following 
senescence progression, heterochromatic silences, 
thus suppressing, the expression of several scavenger 
receptors and endocytosis genes to ultimately reduce 
LSEC endocytic capacity in aging.(77) The mentioned 
deregulations due to aging have a clear effect on 
LSEC response in front of an injury, either acute or 
chronic. In fact, preclinical studies that aimed to ana-
lyze the effects of aging on the liver microcirculation 
demonstrated that LSECs exhibit profound changes 
in response to an injury, including further reduction in 
fenestrae, loss of angiocrine mediators, and decline in 
vasodilators synthesis.(78,79) These alterations have an 
effect on vascular functionality, maintenance of other 
liver cells, and development of clinical complications 
of liver injury including portal hypertension.
HepatiC stellate Cells
HSCs are the main collagen- synthesis cells of the 
liver, and by producing extracellular matrix (ECM) 
and interacting with neighboring cells, they play a 
key role in liver architecture modification and func-
tion. HSCs’ first described function was to store fat 
in the capillary wall of the human liver (also known 
as fat- storing cells or Ito cells). This property has 
led their identification in the liver tissue and their 
isolation using density gradient methods. However, 
during liver damage, these quiescent HSCs acquire 
an “activated” phenotype, losing their fat- storing 
cell phenotype and becoming pro- contractile, pro-
liferative, and matrix- secreting myofibroblast- like 
cells.(80)
In healthy aging, HSCs exhibit a slight, but 
remarkable, activation state, as evidenced by 
increased proliferation, significant increments in the 
expression of specific markers including α- smooth 
muscle actin, collagen I and collagen IV, together 
with increase in inflammatory, pro- oxidant and 
senescence markers, with evidence of matrix depo-
sition within the parenchyma or sinusoids.(69,81) 
Interestingly, and opposite to what is observed in 
chronic liver disease, aged HSCs present increased 
intercellular accumulation of lipids, presumably 
due to alterations in retinoid metabolism and lipid 
breakdown like down- regulation in cellular retinol 
binding protein 1 and overexpression of patatin- like 
phospholipase domain containing 3.
In response to an injury, HSCs become overacti-
vated and therefore actively contribute to the aggra-
vation and perpetuation of liver diseases. Indeed, 
preclinical models of acute liver injury (due to isch-
emia and reperfusion injury) and chronic liver disease 
(due to chronic carbon tetrachloride [CCl4] admin-
istration) in aging demonstrated hyperresponse of 
HSCs, leading to hypercontraction, elevated produc-
tion, and secretion of ECM components, which ulti-
mately led to exaggerated architectural distortion and 
elevation in the hepatic vascular tone.(78)
HepatiC maCRopHages
Liver resident macrophages, also known as 
KCs, are situated in the sinusoidal lumen. KCs are 
exposed to blood, as well as to antigens and bacte-
rial endotoxins, therefore representing the first line 
of defense to maintain immune system in the liver. 
Current evidence indicates that macrophages per-
form a wide repertoire of functions in inflammation 
and repair. The factors determining the behavior of 
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macrophages at sites of inflammation are complex, 
and dependent on several variables of the organ and 
model of tissue injury.(82)
During aging, and in addition to LSECs, KCs 
become pro- inflammatory, displaying elevated levels 
of IL- 6, a cytokine with key roles in liver regener-
ation, infection defense, and metabolism regulation, 
together with alterations in other polarization mak-
ers.(69,83) The pro- inflammatory state of KCs, and 
LSECs may contribute to the recruitment of circu-
lating inflammatory cells including neutrophils and 
monocyte- derived macrophages, observed in aged 
livers. In situations of chronic liver disease, aged 
animals exhibit further deterioration in the hepatic 
inflammatory phenotype, exhibiting increased 
recruitment of inflammatory macrophages together 
with down- regulation in anti- inflammatory and 
pro- resolutive cytokines.(78) The polarization of res-
ident macrophages and the increased myeloid con-
tent in the aged cirrhotic liver may indeed derive 
from the exaggerated activation of the hepatic endo-
thelium (as described previously) and from increased 
gut- derived bacterial products, ultimately aggravat-
ing and perpetuating CLD in aged individuals. In 
Table 1, we summarize the findings on the aging 
process of LSECs, HSCs, and macrophages.
Human Data
Little is known about the effect of aging in the 
human liver sinusoid. Epidemiological data evi-
denced higher prevalence of chronic liver diseases 
coursing with microcirculatory dysfunction in the 
elderly, together with faster progression and worse 
prognosis,(57,84,85) altogether suggesting that the 
hepatic vascular bed might be unprotected in front 
of an injury also in the human being. In accor-
dance with this hypothesis, morphological analysis 
of human livers suggested pseudo- capillarization of 
LSECs and slight activation of HSCs,(86) and recent 
data supported the concept of sinusoidal unprotec-
tion due to aging. In the context of healthy aging, 
characterization of the liver sinusoid in young and 
aged human liver tissues validated most of pheno-
typic deregulations observed in preclinical mod-
els.(69) Human aged livers exhibit features of LSEC 
de- differentiation, as suggested by reduced angioc-
rine and vasodilatory genes, including endothelial 
Fig. 3. Major phenotypic modifications due to aging in liver sinusoidal cells. Abbreviation: HMΦ, hepatic macrophage. (This figure was 
made with BioRender.com under a purchased license agreement.)
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nitric oxide synthase, HGF, laminin subunit beta 
1 and Stab2, together with moderate activation of 
HSCs. In the scenario of chronic liver disease, tran-
scriptomic analysis of liver tissue from patients with 
cirrhosis identified substantial number of genes dif-
ferentially expressed comparing young (<48  years) 
versus old (>58  years) individuals. Comprehensive 
characterization of these data revealed an aged 
cirrhotic signature that, interestingly, included up- 
regulated pathways related to vascular pathobiology, 
thus confirming the deterioration of the sinusoidal 
vascular bed in aged liver disease.(78) These findings, 
detected in well- characterized patients, may have an 
important role in the discovery of new therapeutic 
approaches and treatment of liver diseases in aging. 
Indeed, these findings suggest that future preclini-
cal studies and clinical trials should consider age in 
their design (Fig. 3).
Conclusions
In conclusion, while aging represents one of the 
most important risk factors for several neoplastic 
and nonneoplastic chronic diseases, important issues 
remain to be addressed. For example, the identifica-
tion of appropriate markers of this time- dependent 
process (as a function of disease onset and course) 
may possibly improve translational application of 
preclinical studies in human.(2) Second, inhibition or 
modulation of cellular senescent phenotypes might 
be beneficial in pathological conditions. Finally, 
identification of senescence- related pathways in 
different tissues would possibly allow us to design 
new treatment to organ- specific disease. Preclinical 
animal studies have already shown that ablation of 
senescent cells (obtained by means of specific drugs 
or small interfering RNA treatment) was able to 
improve cardiac reserve in older mice or lifespan in 
progeroid Ercc1_/Δ rodents.(87) Several drugs, includ-
ing dasatinib, quercetin, fisetin and others, have been 
proposed to lead senescent cells toward deletion/
apoptosis.(88) In a pivotal study, intermittent admin-
istration of dasatinib and quercetin was conducted 
for 3  weeks in 14 patients affected by idiopathic 
pulmonary fibrosis. Physical function was improved 
by treatment, with an acceptable safety and toler-
ability.(89) Further findings on senolytic treatment 
in humans were obtained in a study on patients 
with diabetes- related renal disease.(90) This research 
demonstrated, after a 3- day short course of dasati-
nib + quercetin, a reduced number of adipose tissue 
senescent cells and decreased circulating levels of 
SASP. However, large trials on chronic administra-
tion of senolytic treatments would require an accu-
rate evaluation of risk and benefit to be undertaken 
taBle 1. main eFFeCts oF aging on tHe Cells oF liVeR VasCulatuRe
Cell Type Pathophysiological Event Specific Evidence References
LSEC Vasoconstriction ⇩NO, ⇩eNOS, ⇩cGMP, ⇩HO- 1, ⇩KLF2 (69,78)
Inflammation ⇧ICAM, ⇧IL- 6, ⇧CD6, SASP: ⇧(cytokines IL- 1α, IL- 1β, IL- 15, I- L18), ⇧(chemokines Ccl2, Ccl6, 
Ccl8, Ccl24, Cxcl9, Cxcl12, Cxcl13, Cxcl16)
(68,69)
Scavenging dysfunction ⇩SR(FSA), ⇩(Msr1, Marco, ScarB1, ScarB2, CD36r, CD68r, Mrc1, Stab1, Stab2), ⇩(Ox- LDL, 
Ac- LDL)
(75,91)
Angiocrine deregulation ⇩Stab2, ⇩CB32b, ⇩VEGF- R2, ⇩HGF, ⇩Wnt2, ⇩Hamp, ⇩Axin2 (69,78,92)
Capillarization Pseudo- capillarization (partial loss of fenestrae and basement membrane formation) (86,93)
HSC ECM synthesis ⇑α- SMA, ⇑collagen 1α1, ⇑collagen 1α2 (56,69,78)
Proliferation ⇑PDGF- receptor β, ⇑desmin, ⇩telomere length, ⇑Ki67 (69,94)
Hypercontraction ⇑Rhok, ⇑ α- SMA, ⇑LPA (10,95- 97)
Paracrine deregulation ⇑SASP, ⇑SA- β- gal, ⇑p21, ⇑p53, ⇑p16, ⇑IL- 22, ⇑CCN1, ⇑retinoic acid, ⇑SP (42,98,99)
HMΦ Inflammation ⇧ICAM, ⇧IL- 6, ⇩TNFα, ⇩Mrc1, ⇩Arg1, ⇩IL- 10 (68,69,78)
Abbreviations: Ac- LDL, acetylated low- density lipoprotein; CCN1, cellular communication network factor 1; cGMP, cyclic guanine 
monophosphate; Cxcl, chemokine (C- X- C motif ) ligand; eNOS, endothelial nitric oxide synthase; FSA, formaldehyde- treated albumin; 
Hamp, hepcidin antimicrobial peptide; HMΦ, hepatic macrophage; HO- 1, heme oxygenase 1; ICAM, intercellular adhesion molecule; 
KLF2, Krüppel like factor 2; LPA, lysophosphatidic acid; Marco, macrophage receptor with collagenous structure; Mrc1, mannose recep-
tor C- type 1; Msr1, macrophage scavenger receptor 1; Ox- LDL, oxidized low- density lipoprotein; PDGF, platelet- derived growth factor; 
Rhok, Rho- associated protein kinase; ScarB, scavenger receptor class B; Stab2, stabilin- 2; TNF, tumor necrosis factor; VEGF- R2, VEGF 
receptor 2; Wnt2, wingless- type; α- SMA, α- smooth muscle actin.
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in the future. Moreover, a ubiquitous depletion of 
senescent cells might not be beneficial in different 
pathological settings. For instance, in this review we 
reported that the improvement in the animal model 
of cholestasis is not only associated with the abla-
tion of senescent cholangiocytes, but also with the 
induction of senescence in HSCs. We also reported 
that different cells are present within the vascular 
liver compartment that may unevenly react and con-
tribute to the aging/senescent process. This strongly 
suggests that a specific line of research focusing on 
aging of biliary and vascular compartments would 
be necessary to pursue therapeutic options for dis-
eases afflicting these anatomical districts in humans.
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